Journal ArticleDOI
Association of metformin use with cancer incidence and mortality: A meta-analysis
Reads0
Chats0
TLDR
Metformin can reduce the incidence of overall cancer, liver cancer, pancreatic cancer, colorectal cancer and breast cancer as well as the mortality of Overall cancer, Liver cancer and Breast cancer.About:
This article is published in Cancer Epidemiology.The article was published on 2013-06-01. It has received 242 citations till now. The article focuses on the topics: Cancer & Breast cancer.read more
Citations
More filters
Journal ArticleDOI
Systematic review and meta-analysis of the effect of metformin treatment on overall mortality rates in women with endometrial cancer and type 2 diabetes mellitus.
Faustino R. Pérez-López,Vinay Pasupuleti,Ximena Gianuzzi,Gabriela Palma-Ardiles,Wendy Hernandez-Fernandez,Adrian V. Hernandez,Adrian V. Hernandez +6 more
TL;DR: The survival benefit of metformin treatment is associated with a significant reduction in OM irrespective of diabetes status in patients with EC, and suggests that diabetes screening and maintenance of good glycemic control may improve outcomes in EC.
Journal ArticleDOI
Metformin inhibits cell cycle progression of B-cell chronic lymphocytic leukemia cells
Silvia Bruno,Bernardetta Ledda,Claudya Tenca,Silvia Ravera,Anna Maria Orengo,Andrea Nicola Mazzarello,Andrea Nicola Mazzarello,Elisa Pesenti,Salvatore Casciaro,Omar Racchi,Fabio Ghiotto,Cecilia Marini,Gianmario Sambuceti,Andrea Decensi,Franco Fais +14 more
TL;DR: The results indicate that, while CLL cells after stimulation are in the process of building their full survival and cycling armamentarium, the presence of metformin affects this process.
Journal ArticleDOI
Metformin, an Anti-diabetic Drug to Target Leukemia.
TL;DR: The anti-leukemic potential of metformin and its mode of action on leukemia metabolism is explored and it is realized that if cancer cells modify and reprogram their metabolism to feed their intense biochemical needs associated with their runaway proliferation, they develop metabolic addictions that could represent attractive targets for new therapeutic strategies that intend to starve and kill cancer cells.
Journal ArticleDOI
Metformin Induces Cell Cycle Arrest and Apoptosis in Drug-Resistant Leukemia Cells.
A. Rodríguez-Lirio,Gorka Pérez-Yarza,M. R. Fernández-Suárez,Erika Alonso-Tejerina,María-Dolores Boyano,Aintzane Asumendi +5 more
TL;DR: It is demonstrated that metformin exerts varying degrees of antitumor activity against human leukemia cells, as reflected by differences in growth inhibition, apoptosis, and alterations to metabolic enzymes.
Journal ArticleDOI
Association of Metformin Use With Cancer-Specific Mortality in Hepatocellular Carcinoma After Curative Resection: A Nationwide Population-Based Study.
Young Seok Seo,Yun Jung Kim,Mi Sook Kim,Kyung-Suk Suh,Sang Bum Kim,Chul Ju Han,Youn Joo Kim,Won Il Jang,Shin Hee Kang,Ha Jin Tchoe,Chan Mi Park,Ae Jung Jo,Hyo Jeong Kim,Jin A. Choi,Hyung Jin Choi,Michael N. Polak,Min Jung Ko +16 more
TL;DR: In this large population-based cohort of patients with comorbid HCC and T2DM, treated with curative hepatic resection, metformin use was associated with improvement of HCC-specific mortality and reduced occurrence of retreatment events.
References
More filters
Journal ArticleDOI
Measuring inconsistency in meta-analyses
TL;DR: A new quantity is developed, I 2, which the authors believe gives a better measure of the consistency between trials in a meta-analysis, which is susceptible to the number of trials included in the meta- analysis.
Journal ArticleDOI
Bias in meta-analysis detected by a simple, graphical test
TL;DR: Funnel plots, plots of the trials' effect estimates against sample size, are skewed and asymmetrical in the presence of publication bias and other biases Funnel plot asymmetry, measured by regression analysis, predicts discordance of results when meta-analyses are compared with single large trials.
Journal ArticleDOI
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
TL;DR: Those on insulin or insulin secretagogues were more likely to develop solid cancers than those on metformin, and combination with met formin abolished most of this excess risk.
Journal ArticleDOI
New Users of Metformin Are at Low Risk of Incident Cancer: A cohort study among people with type 2 diabetes
Gillian Libby,Louise A. Donnelly,Peter T. Donnan,Dario R. Alessi,Dario R. Alessi,Andrew D. Morris,Josie M M Evans +6 more
TL;DR: Results suggest that metformin use may be associated with a reduced risk of cancer in people with type 2 diabetes, and a randomized trial is needed to assess whether met formin is protective in a population at high risk for cancer.
Journal ArticleDOI
Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis
Andrea Decensi,Matteo Puntoni,Pamela J. Goodwin,Massimiliano Cazzaniga,Alessandra Gennari,Bernardo Bonanni,Sara Gandini +6 more
TL;DR: A comprehensive literature search and meta-analysis of epidemiologic studies to assess the effect of metformin on cancer incidence and mortality in diabetic patients found that the inverse association was significant for pancreatic and hepatocellular cancer, and nonsignificant for colon, breast, and prostate cancer.
Related Papers (5)
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level
I. Ben Sahra,Kathiane Laurent,Kathiane Laurent,Agnès Loubat,Agnès Loubat,Sophie Giorgetti-Peraldi,Sophie Giorgetti-Peraldi,Pascal Colosetti,Pascal Colosetti,Patrick Auberger,Patrick Auberger,Jean-François Tanti,Jean-François Tanti,Y. Le Marchand-Brustel,Y. Le Marchand-Brustel,Frédéric Bost,Frédéric Bost +16 more